187 related articles for article (PubMed ID: 23448474)
1. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
2. Essential structure of opioid κ receptor agonist nalfurafine for binding to κ receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies.
Nagase H; Imaide S; Yamada T; Hirayama S; Nemoto T; Yamaotsu N; Hirono S; Fujii H
Chem Pharm Bull (Tokyo); 2012; 60(8):945-8. PubMed ID: 22863695
[TBL] [Abstract][Full Text] [Related]
3. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.
Nagase H; Imaide S; Hirayama S; Nemoto T; Fujii H
Bioorg Med Chem Lett; 2012 Aug; 22(15):5071-4. PubMed ID: 22742909
[TBL] [Abstract][Full Text] [Related]
4. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
[TBL] [Abstract][Full Text] [Related]
5. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.
Inan S; Lee DY; Liu-Chen LY; Cowan A
Naunyn Schmiedebergs Arch Pharmacol; 2009 Mar; 379(3):263-70. PubMed ID: 18925386
[TBL] [Abstract][Full Text] [Related]
7. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
10. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.
Nakajima R; Yamamoto N; Hirayama S; Iwai T; Saitoh A; Nagumo Y; Fujii H; Nagase H
Bioorg Med Chem; 2015 Oct; 23(19):6271-9. PubMed ID: 26346669
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between
Cao D; Huang P; Chiu YT; Chen C; Wang H; Li M; Zheng Y; Ehlert FJ; Zhang Y; Liu-Chen LY
ACS Chem Neurosci; 2020 Oct; 11(19):3036-3050. PubMed ID: 32897695
[TBL] [Abstract][Full Text] [Related]
14. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Kreek MJ
Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
16. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
17. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
Hasebe K; Kawai K; Suzuki T; Kawamura K; Tanaka T; Narita M; Nagase H; Suzuki T
Ann N Y Acad Sci; 2004 Oct; 1025():404-13. PubMed ID: 15542743
[TBL] [Abstract][Full Text] [Related]
18. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
19. Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.
Huskinson SL; Platt DM; Brasfield M; Follett ME; Prisinzano TE; Blough BE; Freeman KB
Psychopharmacology (Berl); 2020 Jul; 237(7):2075-2087. PubMed ID: 32372348
[TBL] [Abstract][Full Text] [Related]
20. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.
Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
Bioorg Med Chem Lett; 2017 Aug; 27(16):3920-3924. PubMed ID: 28688957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]